



Endometrial Cancer Frontiers: Understanding the Impact of Recent Approvals and Incorporating Precision Diagnostics for Your Patient

Ramez Eskander, MD Moores Cancer Center, UC San Diego, San Diego, CA





Current Endometrial Cancer Treatment Landscape



Immune Checkpoint Inhibition + CT is The New Standard of Care in Advanced Stage or Recurrent dMMR...& pMMR EC?



JULY 31, 20231

FDA approves dostarlimab with chemotherapy for endometrial cancer (dMMR and MSI-H)

DECEMBER 11, 2023²

EC approves dostarlimab with chemotherapy for endometrial cancer (dMMR and MSI-H)

JUNE 14, 2024³

FDA approves durvalumab with chemotherapy for dMMR primary advanced or recurrent endometrial cancer



JANUARY 17, 20257

EC approves dostarlimab with chemotherapy, followed by single agent Dostarlimab for 1L treatment of primary advanced or recurrent endometrial cancer

Highlight Reel

 Mirza MR, et al. N Engl J Med. 2023;388(23):2145-2158. doi:10.1056/nejmoa2216334; 2. GSK. 2023-12-22. GSK's dostarlimab plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer [Press Release]; 3. Westin SN, et al. J Clin Oncol. 2024;42(3):283-299. doi: 10.1200/JCO.23.02132; 4. Eskander RN, et al. N Engl J Med. 2023;388(23):2159-2170. doi:10.1056/NEJMoa2302312; 5. AstraZeneca. 2024-08-14. Olaparib and durvalumab combination approved in the EU for patients with mismatch repair proficient advanced or recurrent endometrial cancer [Press Release]; 6. Merck. 2024-10-24. Merck's pembrolizumab receives 30th approval from European Commission with two new indications in gynecologic cancers [Press Release].; 7. GSK Internal Communications





JUNE 17, 2024⁴

FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial cancer

AUGUST 14, 20245

EC approves durvalumab with chemotherapy for dMMR primary advanced or recurrent endometrial cancer

OCTOBER 24, 2024⁶

EC approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial cancer

Immune Checkpoint Inhibition + CT is The New Standard of Care in Advanced Stage or Recurrent dMMR...& pMMR EC?



None of the FDA indications specify the requirement for measurable disease...?

Essentially all patients enrolled had

DECEMBER measurable/evaluable or recurrent disease

EC approves dostarlimab with chemotherapy for endometrial cancer (dMMR and MSI-H)

JUNE 14, 2024³

mbrolizumab with or primary advanced or recurrent cer

24⁵

EC approves durvalumab with chemotherapy for dMMR primary advanced or recurrent endometrial cancer

FDA approve dMMR prim cancer

JULY 31, 20

FDA approve

endometrial

Clinical Dilemma: Stage 3C1, grade 3 endometrioid adenocarcinoma (dMMR), post-operative CT without radiographic evidence of residual disease...

ibrolizumab with r primary advanced or

etrial cancer

arlimab


024⁶




 Mirza MR, et al. N Engl J Med. 2023;368(23):2143-2136. doi:10.1036/nejint0a2216334; Z. GSN. 2023-12-22. GSN 3 doi:animab plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer [Press Release]; 3. Westin SN, et al. J Clin Oncol. 2024;42(3):283-299. doi: 10.1200/JCO.23.02132; 4. Eskander RN, et al. N Engl J Med. 2023;388(23):2159-2170. doi:10.1056/NEJM0a2302312; 5.AstraZeneca. 2024-08-14. Olaparib and durvalumab combination approved in the EU for patients with mismatch repair proficient advanced or recurrent endometrial cancer [Press Release]; 6. Merck. 2024-10-24. Merck's pembrolizumab receives 30th approval from European Commission with two new indications in gynecologic cancers [Press Release]; 7. GSK Internal Communications



ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 Study of Pembrolizumab or Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer



ENGOT-en11/GOG-3053/KEYNOTE-B21 cont.



Although not a primary hypothesis tested analysis, the HR of 0.31 in dMMR EC is provocative and argues for use of pembrolizumab in combination with chemotherapy in adjuvant setting for dMMR patients

Analogous to expansion of PARPi in stage 2 EOC BRCAmut population

Only 8 recurrences in the pembrolizumab arm..




NCT04634877

Slomovitz B, et al. Presented at: International Gynecologic Cancer Society (IGCS) Annual Global Meeting; 16-18 October 2024; Dublin, Ireland.




ENGOT-en11/GOG-3053/KEYNOTE-B21 cont.




Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: exploratory analyses of biomarker/histological heterogeneity and efficacy in the DUO-E mismatch repair proficient subpopulation (Westin et al.)

- 494 of 575 had POLEm and TP53m information available (~14% missing data)
- HRRm based on identified mutation in 14 pre-defined genes (~14% missing data)
- No data available for patients enrolled in China?




Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: exploratory analyses of biomarker/histological heterogeneity and efficacy in the DUO-E mismatch repair proficient subpopulation (Westin et al.)



pMMR: CP+ durvalumab versus CP

Molecular Profiling in Newly Diagnosed EC

ProMisE Molecular Classification Algorithm^[1]




dMMR, mismatch repair deficient; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; mut, mutated; NSMP, no specific molecular profile; pMMR, proficient MMR; PR, progesterone receptor; TMB-H, tumor mutational burden-high; wt, wild type. Walsh CS, et al. Gynecol Oncol. 2023;168:48-55; 2. NCCN[®]. Uterine Neoplasms (v1.2024). 2023. Accessed November 30, 2023. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf; 3. Berg HG, et al. Br J Cancer. 2023;128:647-655; 3. Jamieson A, et al. J Natl Compr Canc Netw. 2023;21:210-216.


Incorporation of anti-HER-2 treatment: Trastuzumab with Chemotherapy

Key eligibility criteria


- Primary stage III or IV or recurrent HER2/neu-positive USC: IHC score 3+, or 2+ with + FISH
- ECOG 0-2
- ≤3 prior lines of therapy
- "platinum sensitive" recurrence (6 mo)




Nickles-Fader J Clin Oncol 2018




OS benefit particularly striking in stage III–IV patients, OS median of 25.4 months (control) versus NR (p = 0.041, HR = 0.49, 90% CI 0.25–0.97).



Opportunities for chemotherapy free treatment strategies?



LEAP-001: Lenvatinib Plus Pembrolizumab vs Chemo



NCT04865289 Marth C et al. J Clin Oncol 2024



12 15 18 21 24 27 30 33 36 39 42 45 48 51 54

Time (months)


0

0

3 6


9

LEAP-001: Lenvatinib Plus Pembrolizumab vs Chemo



OS - pMMR Population


PFS - pMMR Population



OS - All-comers

Events/Patients		HR (95% CI)	
Overall	442/842		0.93 (0.77-1.12)
Prior neo/adjuvant chemo			
Yes	70/121		0.64 (0.40-1.03)
No	372/721	-	0.96 (0.79-1.18)
	0.1	1	10
	LEN/PEMBRO	better TC b	etter

PFS - All-comers



- OS and PFS were similar between arms for the pMMR and All-Comer populations
- Numerical increases in OS and PFS were observed with lenvatinib/pembrolizumab among patients with prior neoadjuvant/adjuvant chemotherapy

NCT04865289

1. https://clinicaltrials.gov/study/NCT03884101. 2. Marth C et al. ESGO 2024. 3. Marth C et al. SGO 2024. 4. Pignata S et al ESMO-GYN 2024 Abstract 39O.

Evolving Treatment Landscape for the Management of Advanced Stage or Recurrent Endometrial Cancer

